Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$44.85
+0.3%
$51.03
$44.34
$69.10
$90.90B0.3912.14 million shs21.28 million shs
GSK plc stock logo
GSK
GSK
$41.11
+0.5%
$41.83
$33.33
$43.84
$85.20B0.642.90 million shs2.73 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.40
+0.6%
$26.96
$25.20
$40.37
$143.83B0.6134.12 million shs46.53 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$158.42
+3.3%
$171.79
$144.80
$201.92
$72.45B0.854.02 million shs5.24 million shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-0.02%-8.34%-17.30%-9.76%-34.06%
GSK plc stock logo
GSK
GSK
-0.02%+3.42%-4.08%+5.22%+14.42%
Pfizer Inc. stock logo
PFE
Pfizer
+0.08%-2.31%-8.47%-7.54%-34.25%
Zoetis Inc. stock logo
ZTS
Zoetis
0.00%+8.14%-6.33%-17.28%-8.40%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
4.9174 of 5 stars
4.14.02.54.02.31.71.9
GSK plc stock logo
GSK
GSK
2.3932 of 5 stars
0.03.03.30.01.80.02.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9743 of 5 stars
3.23.04.24.83.01.73.1
Zoetis Inc. stock logo
ZTS
Zoetis
4.9293 of 5 stars
3.55.04.20.43.12.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
2.11
Hold$60.0033.78% Upside
GSK plc stock logo
GSK
GSK
2.40
HoldN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3343.04% Upside
Zoetis Inc. stock logo
ZTS
Zoetis
3.00
Buy$218.0037.61% Upside

Current Analyst Ratings

Latest ZTS, BMY, PFE, and GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$55.00 ➝ $48.00
4/26/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $43.00
4/23/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$260.00 ➝ $230.00
4/18/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$51.00 ➝ $52.00
4/16/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$220.00 ➝ $195.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/2/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$215.00 ➝ $195.00
4/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/11/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
(Data available from 4/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$45.53B2.00$12.46 per share3.60$14.49 per share3.10
GSK plc stock logo
GSK
GSK
$37.71B2.26$5.18 per share7.93$7.74 per share5.31
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.46$2.98 per share8.53$15.81 per share1.61
Zoetis Inc. stock logo
ZTS
Zoetis
$8.54B8.48$6.42 per share24.67$10.87 per share14.57

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$8.03B-$3.10N/A6.4316.31-13.50%50.04%16.19%7/25/2024 (Estimated)
GSK plc stock logo
GSK
GSK
$6.13B$3.0113.669.281.4416.24%51.45%10.57%5/1/2024 (Confirmed)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3670.569.171.143.62%10.88%4.91%5/1/2024 (Confirmed)
Zoetis Inc. stock logo
ZTS
Zoetis
$2.34B$5.0731.2524.872.4227.43%51.25%17.58%5/2/2024 (Confirmed)

Latest ZTS, BMY, PFE, and GSK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Zoetis Inc. stock logo
ZTS
Zoetis
$1.35N/A-$1.35N/AN/AN/A  
5/1/2024N/A
GSK plc stock logo
GSK
GSK
$0.95N/A-$0.95N/AN/AN/A  
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/25/2024Q1 24
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
-$4.53-$4.40+$0.13$9.69$11.45 billion$11.87 billion      
2/13/202412/31/2023
Zoetis Inc. stock logo
ZTS
Zoetis
$1.32$1.24-$0.08$1.34$2.19 billion$2.21 billion      
2/2/202412/31/2023
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$1.55$1.70+$0.15$2.53$11.19 billion$11.48 billion    
1/31/2024Q4 2023
GSK plc stock logo
GSK
GSK
$0.76$0.72-$0.04$1.23$9.79 billion$10.00 billion
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
$2.405.35%+8.20%N/A N/A
GSK plc stock logo
GSK
GSK
$1.593.87%-18.20%52.82%1 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.61%+2.57%466.67%15 Years
Zoetis Inc. stock logo
ZTS
Zoetis
$1.731.09%+23.31%34.12%12 Years

Latest ZTS, BMY, PFE, and GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
2/6/2024
Zoetis Inc. stock logo
ZTS
Zoetis
Quarterly$0.43200.88%4/18/20244/19/20246/4/2024
3/1/2024
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
quarterly$0.604.72%4/4/20244/5/20245/1/2024
2/1/2024
GSK plc stock logo
GSK
GSK
quarterly$0.35643.4%2/22/20242/23/20244/11/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
1.24
1.43
1.31
GSK plc stock logo
GSK
GSK
1.19
0.88
0.62
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69
Zoetis Inc. stock logo
ZTS
Zoetis
1.32
3.36
2.00

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
76.41%
GSK plc stock logo
GSK
GSK
15.74%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
0.09%
GSK plc stock logo
GSK
GSK
10.00%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Zoetis Inc. stock logo
ZTS
Zoetis
0.12%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol-Myers Squibb stock logo
BMY
Bristol-Myers Squibb
34,1002.03 billion2.02 billionOptionable
GSK plc stock logo
GSK
GSK
70,2002.07 billion1.87 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
14,100457.36 million456.81 millionOptionable

ZTS, BMY, PFE, and GSK Headlines

SourceHeadline
Zoetis to Sell Medicated Feed Additive Portfolio to Phibro Animal HealthZoetis to Sell Medicated Feed Additive Portfolio to Phibro Animal Health
businesswire.com - April 28 at 6:30 PM
Zoetis (NYSE:ZTS) Shares Up 2.5%Zoetis (NYSE:ZTS) Shares Up 2.5%
americanbankingnews.com - April 28 at 3:58 AM
12,348 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by IMA Wealth Inc.12,348 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by IMA Wealth Inc.
marketbeat.com - April 27 at 4:46 PM
Zoetis (NYSE:ZTS) 9.6% CAGR outpaced the companys earnings growth over the same five-year periodZoetis' (NYSE:ZTS) 9.6% CAGR outpaced the company's earnings growth over the same five-year period
finance.yahoo.com - April 27 at 11:12 AM
ROSEN, A TOP RANKED LAW FIRM, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation - ZTSROSEN, A TOP RANKED LAW FIRM, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation - ZTS
prnewswire.com - April 26 at 10:32 PM
Bryn Mawr Capital Management LLC Acquires 6,170 Shares of Zoetis Inc. (NYSE:ZTS)Bryn Mawr Capital Management LLC Acquires 6,170 Shares of Zoetis Inc. (NYSE:ZTS)
marketbeat.com - April 26 at 9:27 PM
ROSEN, Global Investor Counsel, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation - ZTSROSEN, Global Investor Counsel, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation - ZTS
stockhouse.com - April 26 at 8:11 PM
Behind the Scenes of Zoetiss Latest Options TrendsBehind the Scenes of Zoetis's Latest Options Trends
benzinga.com - April 26 at 8:11 PM
Wall Street Analysts Look Bullish on Zoetis (ZTS): Should You Buy?Wall Street Analysts Look Bullish on Zoetis (ZTS): Should You Buy?
zacks.com - April 26 at 10:31 AM
Jackson Hole Capital Partners LLC Invests $4.15 Million in Zoetis Inc. (NYSE:ZTS)Jackson Hole Capital Partners LLC Invests $4.15 Million in Zoetis Inc. (NYSE:ZTS)
marketbeat.com - April 25 at 9:14 PM
Zoetis (NYSE:ZTS) Stock Price Up 0.2%Zoetis (NYSE:ZTS) Stock Price Up 0.2%
marketbeat.com - April 25 at 7:07 PM
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the FirmINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zoetis Inc. and Encourages Investors with Losses to Contact the Firm
accesswire.com - April 25 at 5:30 PM
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Weeks ReleaseZoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
zacks.com - April 25 at 11:06 AM
Zoetis Foundation Champions Global Veterinarian Education, Well-being, and Livelihoods on World Veterinary Day and BeyondZoetis Foundation Champions Global Veterinarian Education, Well-being, and Livelihoods on World Veterinary Day and Beyond
businesswire.com - April 25 at 7:00 AM
Zoetis (ZTS) Set to Announce Earnings on ThursdayZoetis (ZTS) Set to Announce Earnings on Thursday
americanbankingnews.com - April 25 at 1:28 AM
Bailard Inc. Increases Stock Position in Zoetis Inc. (NYSE:ZTS)Bailard Inc. Increases Stock Position in Zoetis Inc. (NYSE:ZTS)
marketbeat.com - April 24 at 11:47 PM
Zoetis (ZTS) Stock Declines Amid Concerns Over Arthritis Drugs Impacting Pets - Hagens BermanZoetis (ZTS) Stock Declines Amid Concerns Over Arthritis Drugs Impacting Pets - Hagens Berman
markets.businessinsider.com - April 24 at 4:40 PM
Zoetis (NYSE:ZTS) Shares Up 0.8%Zoetis (NYSE:ZTS) Shares Up 0.8%
marketbeat.com - April 24 at 4:22 PM
Zoetis (NYSE:ZTS) Price Target Cut to $230.00 by Analysts at BarclaysZoetis (NYSE:ZTS) Price Target Cut to $230.00 by Analysts at Barclays
americanbankingnews.com - April 24 at 4:54 AM
GAMMA Investing LLC Takes Position in Zoetis Inc. (NYSE:ZTS)GAMMA Investing LLC Takes Position in Zoetis Inc. (NYSE:ZTS)
marketbeat.com - April 23 at 6:52 PM
ROSEN, A TOP RANKED LAW FIRM, Encourages Zoetis Inc. Investors to Inquire About Securities ...ROSEN, A TOP RANKED LAW FIRM, Encourages Zoetis Inc. Investors to Inquire About Securities ...
bakersfield.com - April 23 at 3:35 PM
Zoetis Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)Zoetis Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
markets.businessinsider.com - April 23 at 3:35 PM
Zoetis (ZTS) Fell After Reporting Mixed Fourth Quarter ResultsZoetis (ZTS) Fell After Reporting Mixed Fourth Quarter Results
finance.yahoo.com - April 23 at 3:35 PM
Zoetis (NYSE:ZTS) Shares Up 1.8%Zoetis (NYSE:ZTS) Shares Up 1.8%
marketbeat.com - April 23 at 2:58 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Bristol-Myers Squibb logo

Bristol-Myers Squibb

NYSE:BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Zoetis logo

Zoetis

NYSE:ZTS
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.